AR092658A1 - Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica - Google Patents

Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica

Info

Publication number
AR092658A1
AR092658A1 ARP130103409A ARP130103409A AR092658A1 AR 092658 A1 AR092658 A1 AR 092658A1 AR P130103409 A ARP130103409 A AR P130103409A AR P130103409 A ARP130103409 A AR P130103409A AR 092658 A1 AR092658 A1 AR 092658A1
Authority
AR
Argentina
Prior art keywords
myotonic dystrophy
peptide
treatment
oligonucleotidos
antisentido
Prior art date
Application number
ARP130103409A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR092658A1 publication Critical patent/AR092658A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente memoria se proporcionan oligonucleótidos antisentido morfolino unidos a péptido (PPMO) que están dirigidos a la extensión de repetición poli CUG en la región no traducida 3 del gen que codifica la proteína quinasa de la distrofia miotónica (DMPK) y métodos para la administración sistémica del mismo para el tratamiento de la distrofia miotónica tipo I (DM1).
ARP130103409A 2012-09-25 2013-09-24 Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica AR092658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261705335P 2012-09-25 2012-09-25

Publications (1)

Publication Number Publication Date
AR092658A1 true AR092658A1 (es) 2015-04-29

Family

ID=49301675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103409A AR092658A1 (es) 2012-09-25 2013-09-24 Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica

Country Status (15)

Country Link
US (1) US10111962B2 (es)
EP (1) EP2900821B1 (es)
JP (3) JP6404219B2 (es)
KR (1) KR102240217B1 (es)
CN (1) CN104837997A (es)
AR (1) AR092658A1 (es)
AU (2) AU2013323820B2 (es)
BR (1) BR112015006049A2 (es)
CA (1) CA2886017C (es)
IL (1) IL237457B (es)
MX (1) MX369519B (es)
RU (2) RU2018123569A (es)
SG (2) SG11201501544PA (es)
TW (1) TWI677350B (es)
WO (1) WO2014052276A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960776C (en) * 2013-09-13 2021-11-16 Rutgers, The State University Of New Jersey Multiplex diagnostic assay for lyme disease and other tick-borne diseases
WO2015179742A1 (en) * 2014-05-23 2015-11-26 Genzyme Corporation Multiple oligonucleotide moieties on peptide carrier
WO2015179743A1 (en) * 2014-05-23 2015-11-26 Genzyme Corporation Library and screening approach for improved cell penetrating peptides
EP3297649B1 (en) * 2015-05-19 2023-10-11 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA3005633C (en) * 2015-11-16 2023-11-21 Research Institute Of Nationwide Children's Hospital Materials and methods for treatment of titin-based myopathies and other titinopathies
EP3389719B1 (en) * 2015-12-15 2021-11-17 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2017136435A1 (en) 2016-02-01 2017-08-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
WO2018009547A1 (en) 2016-07-05 2018-01-11 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Diagnosing col6-related disorders and methods for treating same
US10450572B2 (en) * 2016-08-12 2019-10-22 Regents Of The University Of Minnesota Androgen receptor variant inhibitors and methods of using
TWI816703B (zh) * 2017-10-17 2023-10-01 美商薩羅塔治療公司 雙環肽寡核苷酸結合物
US20200316210A1 (en) * 2017-10-17 2020-10-08 Sarepta Therapeutics, Inc. Cell-Penetrating Peptides For Antisense Delivery
MA52148A (fr) * 2018-03-16 2021-01-20 Sarepta Therapeutics Inc Peptides chimères pour administration d'antisens
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR20210081323A (ko) * 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
MX2021014478A (es) * 2019-05-28 2022-01-06 Astellas Pharma Inc Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
GB201911403D0 (en) * 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
WO2021150867A1 (en) * 2020-01-24 2021-07-29 Sarepta Therapeutics, Inc. Designing antisense oligonucleotide delivery peptides by interpretable machine learning
CN117597151A (zh) * 2021-04-30 2024-02-23 日商基因编辑力股份有限公司 强直性肌肉营养不良1型治疗药
WO2022271818A1 (en) * 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2024063570A1 (ko) * 2022-09-23 2024-03-28 주식회사 셀리버리 근긴장성 이영양증 단백질 키나아제를 표적화하는 세포투과성 펩티드 융합 안티센스 올리고뉴클레오티드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JPH0796558B2 (ja) * 1988-03-31 1995-10-18 協和醗酵工業株式会社 修飾ポリペプチド
JP2745351B2 (ja) 1991-02-14 1998-04-28 富士写真フイルム株式会社 ペプチド誘導体及びその用途
US20090286693A1 (en) * 2001-12-12 2009-11-19 New York University, Nyu Medical Center, Department Of Industrial Liaison Microarrays of tagged combinatorial triazine libraries
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
LT2024499T (lt) 2006-05-10 2018-02-26 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2170363B1 (en) * 2007-06-29 2018-08-08 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110269665A1 (en) * 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP6317675B2 (ja) 2011-11-30 2018-04-25 サレプタ セラピューティクス， インコーポレイテッド 延長リピート病を処置するためのオリゴヌクレオチド

Also Published As

Publication number Publication date
TW201424752A (zh) 2014-07-01
CN104837997A (zh) 2015-08-12
US20150238627A1 (en) 2015-08-27
JP2020196751A (ja) 2020-12-10
AU2013323820B2 (en) 2019-06-27
MX2015003841A (es) 2015-07-17
KR102240217B1 (ko) 2021-04-14
JP6404219B2 (ja) 2018-10-10
AU2019203929A1 (en) 2019-07-11
US10111962B2 (en) 2018-10-30
BR112015006049A2 (pt) 2017-08-22
JP2015532264A (ja) 2015-11-09
RU2662962C2 (ru) 2018-07-31
CA2886017C (en) 2022-04-05
MX369519B (es) 2019-11-11
IL237457A0 (en) 2015-04-30
TWI677350B (zh) 2019-11-21
IL237457B (en) 2022-02-01
WO2014052276A1 (en) 2014-04-03
SG10201700751XA (en) 2017-03-30
SG11201501544PA (en) 2015-03-30
RU2018123569A3 (es) 2021-11-09
JP2019006808A (ja) 2019-01-17
RU2015115721A (ru) 2016-11-20
EP2900821A1 (en) 2015-08-05
CA2886017A1 (en) 2014-04-03
RU2018123569A (ru) 2019-03-07
EP2900821B1 (en) 2020-04-01
AU2013323820A1 (en) 2015-04-16
KR20150060738A (ko) 2015-06-03

Similar Documents

Publication Publication Date Title
AR092658A1 (es) Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica
CU20160060A7 (es) Péptidos, ácidos nucleicos y células, útiles en la inmunoterapia personalizada contra diversos tumores cerebrales y neuronales
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
BR112014022562A8 (pt) Formulação de rna para imunoterapia
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
CY1119892T1 (el) Φορεις και αλληλουχιες για την αγωγη ασθενειων
BR112013000391A2 (pt) emulsões de óleo em água catiônicas
MX350258B (es) Emulsiones cationicas de aceite en agua.
CR20150386A (es) Composiciones de nanoparticulas de albumina y paclitaxel
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
BR122021025194A8 (pt) Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna
MX2017015962A (es) Uso de exosomas para el tratamiento de enfermedades.
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
MX342675B (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
CL2014002726A1 (es) Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
BR112013025969A2 (pt) forma de dose unitária para administração oral
CY1116304T1 (el) Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας
CR11519A (es) Vectores de virus oncoliticos de viruela
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
TR201909998T4 (tr) Peptit konjugatlı partiküller.